Skip to main content
Top
Published in: Tumor Biology 1/2013

01-02-2013 | Research Article

The expression and function of microRNA-203 in lung cancer

Authors: Jianhua Jin, Jianzhong Deng, Fang Wang, Xiyi Xia, Tiefeng Qiu, Wenbin Lu, Xianwen Li, Hua Zhang, Xiaoyan Gu, Yungang Liu, Weiguo Cao, Wenlong Shao

Published in: Tumor Biology | Issue 1/2013

Login to get access

Abstract

We aimed to determine the expression of microRNA-203 (miR-203) in human lung cancer cell lines and to evaluate the effects of miR-203 by targeting survivin, on the lung cancer cell line 95-D to provide potential new strategies for treating lung cancer. The expression of miR-203 was detected using quantitative real-time PCR (qRT-PCR) in the in vitro cultured lung cancer cells A549, HCC827, NCI-H1299, and 95-D as well as in normal human bronchial epithelial cells. Following a 72-h transfection with the miR-203 precursor in 95-D lung cancer cells, the change in miR-203 expression was detected using qRT-PCR and the resulting effect on survivin protein expression was ascertained by Western blot analysis. The influence of miR-203 on the viability of 95-D lung cancer cells was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. The effect of miR-203 on 95-D cell proliferation was analyzed using flow cytometry. The consequences of miR-203 expression on 95-D cell apoptosis were analyzed by Annexin V/propidium iodide double staining coupled with flow cytometry. The role of miR-203 in the invasive potential of 95-D cells was studied using a transwell chamber assay. A luciferase reporter gene system was used to verify that survivin is a target gene for miR-203. By qRT-PCR, the expression of miR-203 was lower in lung cancer cells than in normal bronchial epithelial cells (p < 0.01), and the expression of miR-203 in 95-D lung cancer cells was significantly higher after a 72-h transfection with the miR-203 precursor (p < 0.01). After a 72-h transfection with the miR-203 precursor, survivin protein levels in 95-D cells were significantly decreased (p < 0.01). Cell viability, as assessed with an MTT assay, decreased following an increase in miR-203 expression (p < 0.05). The flow cytometry results indicated that after miR-203 expression increased, the cell proliferation index decreased (p < 0.05) and the number of apoptotic cells increased (p < 0.01). Increased miR-203 expression led to a significant decrease in the number of cells that migrated through a transwell chamber membrane (p < 0.01). The luciferase reporter gene system demonstrated that the relative luciferase activity significantly decreased after transfection with the miR-203 precursor (p < 0.05). The expression of miR-203 is downregulated in lung cancer cells. miR-203 negatively regulates survivin protein expression and inhibits the proliferation and invasion of lung cancer cells. Therapeutic strategies that enhance miR-203 expression or silence survivin could potentially benefit lung cancer patients.
Literature
1.
go back to reference Shash E, Peccatori FA, Azim Jr HA. Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). J Thorac Dis. 2011;3(1):57–64.PubMed Shash E, Peccatori FA, Azim Jr HA. Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). J Thorac Dis. 2011;3(1):57–64.PubMed
2.
go back to reference Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res. 2012;1(1):5–13. Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res. 2012;1(1):5–13.
3.
go back to reference Pakkala S, Ramalingam SS. Lung cancer in HIV-positive patients. J Thorac Oncol. 2010;5(11):1864–71.PubMedCrossRef Pakkala S, Ramalingam SS. Lung cancer in HIV-positive patients. J Thorac Oncol. 2010;5(11):1864–71.PubMedCrossRef
4.
go back to reference Lu TP, Tsai MH, Hsiao CK, Lai LC, Chuang EY. Expression and functions of semaphorins in cancer. Transl Cancer Res. 2012;1(2):74–87. Lu TP, Tsai MH, Hsiao CK, Lai LC, Chuang EY. Expression and functions of semaphorins in cancer. Transl Cancer Res. 2012;1(2):74–87.
5.
go back to reference Nieder C, Norum J. Early palliative care in patients with metastatic non-small cell lung cancer. Ann Palliat Med. 2012;1(1):84–6. Nieder C, Norum J. Early palliative care in patients with metastatic non-small cell lung cancer. Ann Palliat Med. 2012;1(1):84–6.
6.
go back to reference Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One. 2012;7(3):e34100.PubMedCrossRef Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One. 2012;7(3):e34100.PubMedCrossRef
7.
go back to reference Chen WQ, Zhang SW, Zou XN, Zhao P. Cancer incidence and mortality in China, 2006. Chin J Cancer Res. 2011;23(1):3–9.CrossRef Chen WQ, Zhang SW, Zou XN, Zhao P. Cancer incidence and mortality in China, 2006. Chin J Cancer Res. 2011;23(1):3–9.CrossRef
8.
go back to reference You WC. Contribution from cancer epidemiological studies in China. Chin J Cancer Res. 2011;23(1):1–2.CrossRef You WC. Contribution from cancer epidemiological studies in China. Chin J Cancer Res. 2011;23(1):1–2.CrossRef
9.
go back to reference Park BJ. Robotic lobectomy for non-small cell lung cancer (NSCLC): multi-registry study of long-term oncologic results. Ann Cardiothorac Surg. 2012;1(1):24–6. Park BJ. Robotic lobectomy for non-small cell lung cancer (NSCLC): multi-registry study of long-term oncologic results. Ann Cardiothorac Surg. 2012;1(1):24–6.
10.
go back to reference Wang YX. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg. 2011;1(1):35–40.PubMed Wang YX. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg. 2011;1(1):35–40.PubMed
11.
go back to reference Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, Matsumura Y. Exosome can prevent RNase from degrading microRNA in feces. J Gastrointest Oncol. 2011;2(4):215–22.PubMed Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, Matsumura Y. Exosome can prevent RNase from degrading microRNA in feces. J Gastrointest Oncol. 2011;2(4):215–22.PubMed
12.
go back to reference Wall N. Colorectal cancer screening using protected microRNAs. J Gastrointest Oncol. 2011;2(4):206–7.PubMed Wall N. Colorectal cancer screening using protected microRNAs. J Gastrointest Oncol. 2011;2(4):206–7.PubMed
13.
go back to reference Meng F, Francis H, Alpini G. Non-coding RNAs in human liver malignancies, critical regulators for cancer stemness? Transl Gastrointest Cancer. 2012;1(1):1–4. Meng F, Francis H, Alpini G. Non-coding RNAs in human liver malignancies, critical regulators for cancer stemness? Transl Gastrointest Cancer. 2012;1(1):1–4.
14.
go back to reference Knuckles P, Vogt MA, Lugert S, Milo M, Chong MM, Hautbergue GM, Wilson SA, Littman DR, Taylor V. Drosha regulates neurogenesis by controlling neurogenin 2 expression independent of microRNAs. Nat Neurosci. 2012;15(7):962–9.PubMedCrossRef Knuckles P, Vogt MA, Lugert S, Milo M, Chong MM, Hautbergue GM, Wilson SA, Littman DR, Taylor V. Drosha regulates neurogenesis by controlling neurogenin 2 expression independent of microRNAs. Nat Neurosci. 2012;15(7):962–9.PubMedCrossRef
15.
go back to reference Shu GS, Yang ZL, Liu DC. Immunohistochemical study of Dicer and Drosha expression in the benign and malignant lesions of gallbladder and their clinicopathological significances. Pathol Res Pract. 2012;208(7):392–7.PubMedCrossRef Shu GS, Yang ZL, Liu DC. Immunohistochemical study of Dicer and Drosha expression in the benign and malignant lesions of gallbladder and their clinicopathological significances. Pathol Res Pract. 2012;208(7):392–7.PubMedCrossRef
16.
go back to reference Tan GS, Garchow BG, Liu X, Metzler D, Kiriakidou M. Clarifying mammalian RISC assembly in vitro. BMC Mol Biol. 2011;12:19.PubMedCrossRef Tan GS, Garchow BG, Liu X, Metzler D, Kiriakidou M. Clarifying mammalian RISC assembly in vitro. BMC Mol Biol. 2011;12:19.PubMedCrossRef
17.
go back to reference Hebert SS, Sergeant N, Buee L. MicroRNAs and the regulation of tau metabolism. Int J Alzheimers Dis. 2012;2012:406561.PubMed Hebert SS, Sergeant N, Buee L. MicroRNAs and the regulation of tau metabolism. Int J Alzheimers Dis. 2012;2012:406561.PubMed
18.
go back to reference Ui-Tei K, Nishi K, Takahashi T, Nagasawa T. Thermodynamic control of small RNA-mediated gene silencing. Front Genet. 2012;3:101.PubMed Ui-Tei K, Nishi K, Takahashi T, Nagasawa T. Thermodynamic control of small RNA-mediated gene silencing. Front Genet. 2012;3:101.PubMed
19.
go back to reference Yang JS, Maurin T, Lai EC. Functional parameters of Dicer-independent microRNA biogenesis. RNA. 2012;18(5):945–57.PubMedCrossRef Yang JS, Maurin T, Lai EC. Functional parameters of Dicer-independent microRNA biogenesis. RNA. 2012;18(5):945–57.PubMedCrossRef
20.
go back to reference Wang J, Li LC. Small RNA and its application in andrology and urology. Transl Androl Urol. 2012;1(1):33–43.PubMed Wang J, Li LC. Small RNA and its application in andrology and urology. Transl Androl Urol. 2012;1(1):33–43.PubMed
21.
go back to reference Aliotta J. Tumor exosomes: a novel biomarker? J Gastrointest Oncol. 2011;2(4):203–5.PubMed Aliotta J. Tumor exosomes: a novel biomarker? J Gastrointest Oncol. 2011;2(4):203–5.PubMed
22.
go back to reference Yu J, Li A, Hong SM, Hruban RH, Goggins M. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res. 2012;18(4):981–92.PubMedCrossRef Yu J, Li A, Hong SM, Hruban RH, Goggins M. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res. 2012;18(4):981–92.PubMedCrossRef
23.
go back to reference Luzna P, Gregar J, Uberall I, Radova L, Prochazka V, Ehrmann Jr J. Changes of microRNAs-192, 196a and 203 correlate with Barrett’s esophagus diagnosis and its progression compared to normal healthy individuals. Diagn Pathol. 2011;6:114.PubMedCrossRef Luzna P, Gregar J, Uberall I, Radova L, Prochazka V, Ehrmann Jr J. Changes of microRNAs-192, 196a and 203 correlate with Barrett’s esophagus diagnosis and its progression compared to normal healthy individuals. Diagn Pathol. 2011;6:114.PubMedCrossRef
24.
go back to reference Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13(6):496–506.PubMedCrossRef Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13(6):496–506.PubMedCrossRef
25.
go back to reference Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H, Fujita H, Nakata K, Tanaka M. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17(12):3120–8.PubMedCrossRef Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H, Fujita H, Nakata K, Tanaka M. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17(12):3120–8.PubMedCrossRef
26.
go back to reference McKenzie JA, Grossman D. Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res. 2012;32(2):397–404.PubMed McKenzie JA, Grossman D. Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res. 2012;32(2):397–404.PubMed
27.
go back to reference Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep. 2012;14(2):120–8.PubMedCrossRef Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep. 2012;14(2):120–8.PubMedCrossRef
28.
go back to reference Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y, Dahiya R. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res. 2011;17(16):5287–98.PubMedCrossRef Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y, Dahiya R. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res. 2011;17(16):5287–98.PubMedCrossRef
29.
go back to reference Gower AC, Steiling K, Brothers 2nd JF, Lenburg ME, Spira A. Transcriptomic studies of the airway field of injury associated with smoking-related lung disease. Proc Am Thorac Soc. 2011;8(2):173–9.PubMedCrossRef Gower AC, Steiling K, Brothers 2nd JF, Lenburg ME, Spira A. Transcriptomic studies of the airway field of injury associated with smoking-related lung disease. Proc Am Thorac Soc. 2011;8(2):173–9.PubMedCrossRef
30.
go back to reference Hassanein M, Rahman JS, Chaurand P, Massion PP. Advances in proteomic strategies toward the early detection of lung cancer. Proc Am Thorac Soc. 2011;8(2):183–8.PubMedCrossRef Hassanein M, Rahman JS, Chaurand P, Massion PP. Advances in proteomic strategies toward the early detection of lung cancer. Proc Am Thorac Soc. 2011;8(2):183–8.PubMedCrossRef
31.
go back to reference Ellis PM, Vandermeer R. Delays in the diagnosis of lung cancer. J Thorac Dis. 2011;3(3):183–8.PubMed Ellis PM, Vandermeer R. Delays in the diagnosis of lung cancer. J Thorac Dis. 2011;3(3):183–8.PubMed
32.
go back to reference Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524–9.PubMedCrossRef Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524–9.PubMedCrossRef
33.
go back to reference Cho WC. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets. 2012;16(8):747–59.PubMedCrossRef Cho WC. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets. 2012;16(8):747–59.PubMedCrossRef
34.
go back to reference Xiao DK, He JX. Epithelial mesenchymal transition and lung cancer. J Thorac Dis. 2010;2(3):154–9.PubMed Xiao DK, He JX. Epithelial mesenchymal transition and lung cancer. J Thorac Dis. 2010;2(3):154–9.PubMed
35.
go back to reference Izzotti A, Cartiglia C, Steele VE, De Flora S. MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res. 2012;751(2):287–303.PubMedCrossRef Izzotti A, Cartiglia C, Steele VE, De Flora S. MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res. 2012;751(2):287–303.PubMedCrossRef
36.
go back to reference Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M, Nusbaum JD, Feederle R, Delecluse HJ, Luftig MA, et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog. 2012;8(1):e1002484.PubMedCrossRef Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M, Nusbaum JD, Feederle R, Delecluse HJ, Luftig MA, et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog. 2012;8(1):e1002484.PubMedCrossRef
37.
go back to reference Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, Qiao C, Xu J, Li J. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett. 2011;309(1):62–70.PubMedCrossRef Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, Qiao C, Xu J, Li J. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett. 2011;309(1):62–70.PubMedCrossRef
38.
go back to reference Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011;305(1):59–67.PubMedCrossRef Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011;305(1):59–67.PubMedCrossRef
39.
go back to reference Dong C, Ji M, Ji C. microRNAs and their potential target genes in leukemia pathogenesis. Cancer Biol Ther. 2009;8(3):200–5.PubMedCrossRef Dong C, Ji M, Ji C. microRNAs and their potential target genes in leukemia pathogenesis. Cancer Biol Ther. 2009;8(3):200–5.PubMedCrossRef
40.
go back to reference Bostjancic E, Glavac D. Importance of microRNAs in skin morphogenesis and diseases. Acta Dermatovenerol Alp Panonica Adriat. 2008;17(3):95–102.PubMed Bostjancic E, Glavac D. Importance of microRNAs in skin morphogenesis and diseases. Acta Dermatovenerol Alp Panonica Adriat. 2008;17(3):95–102.PubMed
41.
go back to reference Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. FEBS J. 2011;278(10):1598–609.PubMedCrossRef Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. FEBS J. 2011;278(10):1598–609.PubMedCrossRef
42.
go back to reference Bian K, Fan J, Zhang X, Yang XW, Zhu HY, Wang L, Sun JY, Meng YL, Cui PC, Cheng SY, et al. MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett. 2012;586(6):804–9.PubMedCrossRef Bian K, Fan J, Zhang X, Yang XW, Zhu HY, Wang L, Sun JY, Meng YL, Cui PC, Cheng SY, et al. MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett. 2012;586(6):804–9.PubMedCrossRef
43.
go back to reference Wang C, Zheng X, Shen C, Shi Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31:58.PubMedCrossRef Wang C, Zheng X, Shen C, Shi Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31:58.PubMedCrossRef
Metadata
Title
The expression and function of microRNA-203 in lung cancer
Authors
Jianhua Jin
Jianzhong Deng
Fang Wang
Xiyi Xia
Tiefeng Qiu
Wenbin Lu
Xianwen Li
Hua Zhang
Xiaoyan Gu
Yungang Liu
Weiguo Cao
Wenlong Shao
Publication date
01-02-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0556-3

Other articles of this Issue 1/2013

Tumor Biology 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine